Ultragenyx Pharmaceutical Inc. (RARE) Stock
RARE has an Alpha Score of 21 out of 100 (poor), computed on Nov 4, 2026 from 2 of 4 sub-scores. 1 member of Congress disclosed 5 trades in RARE since 2025: 5 purchases and 0 sales, most recently Gilbert Cisneros (purchase, Sep 29, 2026). 6 of the hedge funds AlphaScala tracks reported RARE in 13F filings for the quarter ended Sep 30, 2026; the largest reported position is D.E. Shaw's at $57.77M. Company insiders reported 0 open-market buys and 3 sales on SEC Form 4 in the 90 days to Nov 5, 2026.
What is RARE's Alpha Score?
How it works →Alpha Score of 21 reflects poor overall profile with weak momentum, poor quality. Based on 2 of 4 signals – score is capped at 75 until remaining data ingests.
Computed from 2 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 4, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which members of Congress traded Ultragenyx Pharmaceutical Inc. (RARE)?
Most recent: Gilbert Cisneros (purchase, Sep 29, 2026); records start Jul 15, 2025.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Gil Cisneros D-CA · House | 2026-09-29 | purchase | $1k – $15k |
| Gil Cisneros D-CA · House | 2026-03-03 | purchase | $1k – $15k |
| Gil Cisneros D-CA · House | 2026-02-18 | purchase | $1k – $15k |
| Gil Cisneros D-CA · House | 2025-08-08 | purchase | $1k – $15k |
| Gil Cisneros D-CA · House | 2025-07-15 | purchase | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Nov 5, 2026.
See all RARE political trades →Which hedge funds own RARE?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| D.E. Shaw David Shaw | 1.73M | $57.77M | +37% |
| Millennium Management Israel Englander | 761K | $25.40M | -57% |
| Renaissance Technologies Jim Simons (founder) | 414K | $13.81M | -26% |
| Citadel Ken Griffin | 211K | $7.03M | -90% |
| Marshall Wace | 160K | $5.34M | +2% |
| Hussman Investment Trust John Hussman | 105K | $1.58M | NEW |
13F holdings as of Sep 30, 2026
Explore all tracked funds →Are Ultragenyx Pharmaceutical Inc. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Oct 15, 26 | Horn Howard | Chief Financial Officer | SELL | 7.1K | $108K |
| Sep 15, 26 | Huizenga Theodore Alan | SVP, Chief Accounting Officer | SELL | 1.3K | $17K |
| Sep 3, 26 | Huizenga Theodore Alan | SVP, Chief Accounting Officer | SELL | 161 | $2K |
| Aug 3, 26 | Horn Howard | Chief Financial Officer | SELL | 4.7K | $117K |
| Aug 3, 26 | Parschauer Karah Herdman | EVP and Chief Legal Officer | SELL | 1.9K | $47K |
SEC Form 4 filings as of Nov 5, 2026
See cluster-buy signals across all tickers →What are RARE's key statistics?
Key statistics as of Oct 28, 2026
How does RARE's valuation compare with the Healthcare sector?
| Metric | RARE | Healthcare median | Companies in median |
|---|---|---|---|
| Net margin | -81.73% | 4.11% | 160 |
| Return on equity | -414.17% | 5.18% | 180 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 6, 2026). P/E excludes loss-making companies.
RARE price chart
Powered by TradingViewWhat does Ultragenyx Pharmaceutical Inc. do?
Ultragenyx Pharmaceutical is a biopharmaceutical company focused on identifying, acquiring, developing, and commercializing novel products for treating rare and ultra-rare genetic diseases across North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific region. The company's approved commercial products include Crysvita (burosumab), an antibody for X-linked hypophosphatemia; Mepsevii, an enzyme replacement therapy for mucopolysaccharidosis VII; Dojolvi for long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for homozygous familial hypercholesterolemia. Ultragenyx maintains a robust clinical pipeline featuring multiple late-stage candidates in Phase 3 development, including UX111, an AAV9 gene therapy for Sanfilippo syndrome type A; DTX401, an AAV8 gene therapy for glycogen storage disease type Ia; UX143, a monoclonal antibody for osteogenesis imperfecta; and GTX-102, an antisense oligonucleotide for Angelman syndrome. Founded in 2010 and headquartered in Novato, California, the company operates globally to address unmet medical needs in rare genetic disease treatment.